Kathleen Gray

Johnson & Johnson (United States) — United States

Medicine · Health Sciences

17h-index777citations55works7.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(35), Protein Degradation and Inhibitors(15), Viral-associated cancers and disorders(7), Peptidase Inhibition and Analysis(7), Cytomegalovirus and herpesvirus research(6)

Publications55 total

Relative Effectiveness of Talquetamab Versus Real-World Physician’s Choice Treatment Regimens in Patients With Relapsed/Refractory Multiple Myeloma: Updated Results From an Indirect Treatment Comparison
Clinical Lymphoma Myeloma & Leukemia·2025
A Phase 2 Study Measuring MRD Negativity after Talquetamab and Teclistamab Consolidation in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC)
Clinical Lymphoma Myeloma & Leukemia·2025
Updated Comparative Effectiveness of Talquetamab vs Real-World Physician’s Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025Open Access
POSTER: MM-216 Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome and Outpatient Dosing of Talquetamab in Relapsed/Refractory Multiple Myeloma: Updated Phase 1/2 Monumental-1 Results
Clinical Lymphoma Myeloma & Leukemia·2025
MM-216: Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome and Outpatient Dosing of Talquetamab in Relapsed/Refractory Multiple Myeloma: Updated Phase 1/2 Monumental-1 Results
Clinical Lymphoma Myeloma & Leukemia·2025
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1
Blood Advances·2025· 2 citedOpen Access
Prophylactic interventions for oral toxicities with the GPRC5D×CD3 bispecific antibody talquetamab in relapsed/refractory multiple myeloma: An update on the open-label, phase 2, randomized TALISMAN study.
Journal of Clinical Oncology·2025
Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab: Highlights From Pharmacists’ Perspectives
Journal of the Advanced Practitioner in Oncology·2025· 1 citedOpen Access
Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies
Clinical Lymphoma Myeloma & Leukemia·2025· 7 citedOpen Access
A Phase II Study Measuring MRD Negativity after Bispecific T-Cell Redirectors Talquetamab and Teclistamab Consolidation Used in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC), Nordic Myeloma Study Group
Blood·2024· 1 cited
Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study
Blood·2024
Satisfaction and Experiences with Talquetamab: Results from Qualitative Patient and Physician Research
Blood·2024
P-077 Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study
Clinical Lymphoma Myeloma & Leukemia·2024· 5 cited
P-409 Real-Life Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Carfilzomiband/or Pomalidomide-Based Regimens in the LocoMMotion and MoMMent Studies
Clinical Lymphoma Myeloma & Leukemia·2024
P-066 Prophylactic Interventions for Oral Toxicities With the GPRC5D×CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase 2, Randomized Study (TALISMAN)
Clinical Lymphoma Myeloma & Leukemia·2024· 3 cited
P-099 Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
Seminars in Oncology Nursing·2024· 5 citedOpen Access
Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2024· 4 cited
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab
Clinical Lymphoma Myeloma & Leukemia·2024· 33 citedOpen Access
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Blood Cancer Journal·2024· 6 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Thomas Renaud(14), Tara Masterson(9), Niels W.C.J. van de Donk(8), Jaszianne Tolbert(8), Shuchita Kaila(8), Colleen Kane(7), Michela Campagna(7), Larysa Sanchez(7), Brandi Hilder(6), Christoph Heuck(6), John R. Anderson(6), Samuel H. Speck(6), Keqin Qi(6), Carolina Schinke(6), Paula Rodríguez‐Otero(5), Ajai Chari(5), G. P. Sandilands(5), Leo Rasche(5), Brea Lipe(5), Shebli Atrash(5)